中华医学会肝病学分会关于重新定义脂肪性肝病的立场声明
中华医学会肝病学分会组织各省市肝病与消化专家就脂肪性肝病定义达成共识,支持将非酒精性脂肪性肝病(NAFLD)更名为代谢功能障碍相关脂肪性肝病(MAFLD),并采用不依赖饮酒量或其他肝病的阳性诊断标准,该提议获95.45%参与者支持。
要点
- 中国脂肪肝发病率最高,超过欧美国家。
- 国际共识建议将NAFLD更名为MAFLD并采用阳性诊断标准。
- 中华医学会肝病学分会以95.45%支持率认可更名。
核心结论
- 中华医学会肝病学分会支持将NAFLD更名为MAFLD,并采用不依赖饮酒量或其他肝病的阳性诊断标准。
研究设计与样本
- 中华医学会肝病学分会邀请各省市肝病与消化专家达成共识,形成立场声明。
主要发现
- 中国脂肪肝发病率最高,超过欧洲国家和美国。
- 更名提议获得95.45%的参与者支持。
关键数值与推荐
- MAFLD诊断采用一套阳性标准,独立于酒精摄入或其他肝病。
临床怎么用
- 新定义预期将改善患者医疗、提升疾病认知、推动公共卫生政策及科研资助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fatty liver disease associated with metabolic dysfunction is of increasing concern in mainland China, the world's most populous country. The incidence of fatty liver disease is highest in China, surpassing the incidence in European countries and the USA. An international consensus panel recently published an influential report recommending a novel definition of fatty liver disease associated with metabolic dysfunction. This recommendation includes a switch in name from non-alcoholic fatty liver disease (NAFLD) to metabolic (dysfunction)-associated fatty liver disease (MAFLD) and adoption of a set of positive criteria for disease diagnosis that are independent of alcohol intake or other liver diseases. Given the unique importance of this proposal, the Chinese Society of Hepatology (CSH) invited leading hepatologists and gastroenterologists representing their respective provinces and cities to reach consensus on alternative definitions for fatty liver disease from a national perspective. The CSH endorses the proposed change from NAFLD to MAFLD (supported by 95.45% of participants). We expect that the new definition will result in substantial improvements in health care for patients and advance disease awareness, public health policy, and political, scientific and funding outcomes for MAFLD in China.
引用
- Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021. PMID: 34019941. doi:10.1016/j.jhep.2021.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。